Stock screener

RLAY

Conviction 100HealthcareScan · Mon, Aug 10, 2026
RLAY$19.94+0.83%
ResistanceSupportVol 14Insider sell
63 bars
2
5
Vol MA14 2.66M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Relay Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.relaytx.com
Price19.94
Change+0.83%
Gap-0.94%
Rel volume4.57×
Avg volume2.56M
Avg $ vol49.36M
SMA 2019.21
SMA 5017.70
SMA 20011.74
Price vs 50+12.62%
Price vs 200+69.81%
MA stackbullish
50/200 cross
Supertrendup · 16.85
RSI (14)61
MACD hist-0.02
MACD cross
Stoch %K / %D74 / 77
ADX (14)26
+DI / −DI27 / 16
RSI divergence
MACD divergence
ATR %+5.46%
ADR %5.40%
52w high20.75
52w low3.22
From 52w high-3.93%
Above 52w low+519.10%
New 52w highNo
SqueezeOn · 8d
Bollinger width10.39%
%B0.86
Donchian pos74.17%
Donchian high20.71
Donchian low17.71
AVWAP (52w high)19.41
vs AVWAP high+2.68%
AVWAP (52w low)11.66
vs AVWAP low+70.90%
OBV trendUp
Chaikin MF (20)-0.04
Today vs 20d4.57×
Avg vol (14d)2.66M
Avg vol (20d)2.56M
Avg $ vol (20d)49.36M
Market cap4.37B
RS 3m (vs SPY)+52.34%
RS 6m (vs SPY)+128.46%
RS line new highNo
Trend template8/8
Technical rank90.0
1 week+6.15%
1 month-0.35%
3 months+56.23%
6 months+123.49%
1 year+471.20%
YTD+143.70%
P/E-15.80
P/B4.91
P/S284.51
P/FCF-18.52
EPS-1.61
Div yield
ROE-31.06%
ROA-28.58%
Debt/Eq
Current18.27
EV/EBITDA
Gross margin
Net margin
Rev growth53.44%
EPS growth18.13%
Price target26.20
Target upside31.43%
Analyst ratingBuy
Institutional94.15%
Ent. value4.25B
Revenue350K
Net income-83.71M
Gross profit
Free cash flow-235.87M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out191.59M
Employees192
ListedThu, Jul 16, 2020
Free float116.71M
Float %65.3%
Short interest42.56M
Days to cover13.4d
Short volume78.2%
Squeeze score100 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.41 vs −$0.41
Last surprise0.0% beat
Setup gradeA+
Conviction100 / 100
Pattern quality
Tech rank90.0 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance20.59
Support17.69
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RLAY

All disclosures →
No recent disclosed trades by Congress in RLAY. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RLAY · 4 buys · 6 sells

InsiderSideShares
Patel Sanjiv
President and CEO · Common Stock · 2026-07-07
Sell48.2K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-07-06
Sell17.72K
Bergstrom Donald A
President, R&D · Common Stock · 2026-07-06
Sell8.66K
Patel Sanjiv
President and CEO · Common Stock · 2026-06-30
Grant3.06K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell17.72K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Exercise56.32K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell56.32K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Exercise61.56K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell61.56K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Exercise51.56K

SEC filings

EDGAR filings in RLAY · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.